KYORIN Pharmaceutical Co., Ltd.
Q1 FY2027 Financial Results Supplementary Materials
The company's sales for the first quarter of FY2027 were ¥29.7 billion, a decrease of ¥5.75 hundred million YoY; operating profit was ¥1.0 billion, down ¥1.4 hundred million; net profit was ¥824 million, a 60.8% decline. Sales were affected by a decrease in domestic new pharmaceuticals.
Key Figures
- Sales: ¥29.7 billion (YoY -¥5.75 hundred million)
- Operating Income: ¥1.0 billion (YoY -¥1.44 billion)
- Net Income Attributable to Owners of Parent: ¥824 million (60.8% decrease)
AI要約
Summary of Business Performance
The consolidated sales for the first quarter of FY2027 were ¥29.7 billion, a decline of ¥5.75 hundred million YoY, mainly due to a decrease in sales of domestic new pharmaceuticals. Operating profit was ¥1.0 billion, down ¥1.44 hundred million, and net profit also dropped significantly to ¥824 million. Increased costs and drug price revisions compressed profit margins.
Outlook and Investor Impact
The company continues to promote the expansion of new drug sales and cost management, but the downward trend in sales and profits persists. The progress rate for Q2 is projected at 51.3% for sales and 48.2% for operating profit, making careful consideration of full-year forecasts necessary. Investors should monitor performance recovery trends and progress in new drug development.
Kyorin Pharmaceutical
Company overview · Stock price · Financial data · All IR
